scholarly journals Swiss Personalized Health Network (SPHN): Die nationale Initiative im Überblick

2017 ◽  
Vol 98 (19) ◽  
pp. 595-596 ◽  
10.2196/27591 ◽  
2021 ◽  
Author(s):  
Christophe Gaudet-Blavignac ◽  
Jean Louis Raisaro ◽  
Vasundra Touré ◽  
Sabine Österle ◽  
Katrin Crameri ◽  
...  

2021 ◽  
Vol 11 (23) ◽  
pp. 11311
Author(s):  
Philip Krauss ◽  
Vasundra Touré ◽  
Kristin Gnodtke ◽  
Katrin Crameri ◽  
Sabine Österle

One goal of the Swiss Personalized Health Network (SPHN) is to provide an infrastructure for FAIR (Findable, Accessible, Interoperable and Reusable) health-related data for research purposes. Semantic web technology and biomedical terminologies are key to achieving semantic interoperability. To enable the integrative use of different terminologies, a terminology service is a important component of the SPHN Infrastructure for FAIR data. It provides both the current and historical versions of the terminologies in an SPHN-compliant graph format. To minimize the usually high maintenance effort of a terminology service, we developed an automated CI/CD pipeline for converting clinical and biomedical terminologies in an SPHN-compatible way. Hospitals, research infrastructure providers, as well as any other data providers, can download a terminology bundle (currently composed of SNOMED CT, LOINC, UCUM, ATC, ICD-10-GM, and CHOP) and deploy it in their local terminology service. The distributed service architecture allows each party to fulfill their local IT and security requirements, while still having an up-to-date interoperable stack of SPHN-compliant terminologies. In the future, more terminologies and mappings will be added to the terminology service according to the needs of the SPHN community.


2020 ◽  
Vol 11 ◽  
Author(s):  
Alessandro Blasimme ◽  
Caroline Brall ◽  
Effy Vayena

In 2017 the Swiss federal government established the Swiss Personalized Health Network (SPHN), a nationally coordinated data infrastructure for genetic research. The SPHN advisory group on Ethical, Legal, and Social Implications (ELSI) was tasked with the creation of a recommendation to ensure ethically responsible reporting of genetic research findings to research participants in SPHN-funded studies. Following consultations with expert stakeholders, including geneticists, pediatricians, sociologists, university hospitals directors, patient representatives, consumer protection associations, and insurers, the ELSI advisory group issued its recommendation on “Reporting actionable genetic findings to research participants” in May 2020. In this paper we outline the development of this recommendation and the provisions it contains. In particular, we discuss some of its key features, namely: (1) that participation in SPHN-funded studies as a research subject is conditional to accepting that medically relevant genetic research findings will be reported; (2) that a Multidisciplinary Expert Panel (MEP) should be created to support researchers’ decision-making processes about reporting individual genetic research findings; (3) that such Multidisciplinary Expert Panel will make case-by-case decisions about whether to allow reporting of genetic findings, instead of relying on a pre-defined list of medically relevant variants; (4) that research participants shall be informed of the need to disclose genetic mutations when applying for private insurance, which may influence individual decisions about participation in research. By providing an account of the procedural background and considerations leading to the SPHN recommendation on “Reporting actionable genetic findings to research participants,” we seek to promote a better understanding of the proposed guidance, as well as to contribute to the global dialog on the reporting of genetic research findings.


2011 ◽  
Vol 45 (1) ◽  
pp. 29
Author(s):  
JONATHAN M. SPECTOR

2015 ◽  
Vol 14 (2) ◽  
pp. 105-110

Guest editor Teresa De Marco, MD, along with Brian Shapiro, MD, Mayo Clinic, Jacksonville, FL, convened a panel of experts to discuss the challenges in diagnosis and treatment and the emerging science regarding pulmonary hypertension due to left heart disease. Contributing to the engaging discussion were James Fang, MD, University of Utah School of Medicine; Barry Borlaug, MD, Mayo Clinic, Rochester, MN; and Srinivas Murali, MD, Allegheny Health Network, Pittsburgh, PA.


Sign in / Sign up

Export Citation Format

Share Document